SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2020 - 2023)
Historic Net Income towards Common Stockholders for SELLAS Life Sciences (SLS) over the last 7 years, with Q4 2023 value amounting to -$8.2 million.
- SELLAS Life Sciences' Net Income towards Common Stockholders rose 1343.43% to -$8.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$8.2 million, marking a year-over-year increase of 7910.73%. This contributed to the annual value of -$37.9 million for FY2023, which is 830.97% up from last year.
- As of Q4 2023, SELLAS Life Sciences' Net Income towards Common Stockholders stood at -$8.2 million, which was up 1343.43% from -$9.4 million recorded in Q3 2023.
- In the past 5 years, SELLAS Life Sciences' Net Income towards Common Stockholders ranged from a high of -$2.4 million in Q1 2021 and a low of -$16.7 million during Q1 2022
- Over the past 4 years, SELLAS Life Sciences' median Net Income towards Common Stockholders value was -$7.1 million (recorded in 2021), while the average stood at -$7.3 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 4307.04% in 2021, then tumbled by 59642.11% in 2022.
- Over the past 4 years, SELLAS Life Sciences' Net Income towards Common Stockholders (Quarter) stood at -$3.7 million in 2020, then crashed by 77.56% to -$6.6 million in 2021, then plummeted by 43.16% to -$9.4 million in 2022, then grew by 13.43% to -$8.2 million in 2023.
- Its Net Income towards Common Stockholders stands at -$8.2 million for Q4 2023, versus -$9.4 million for Q3 2023 and -$9.0 million for Q2 2023.